Press Release

Publication in Journal for ImmunoTherapy in Cancer Highlights Fluorine 19 MRI Cell Tracking

October 11, 2018 – Pittsburgh, Pennsylvania

Celsense, Inc. announced today the publication of an article that reviews recent research into the use of fluorine 19 MRI to track the administration, migration, and persistence of immune cells to treat cancer in the peer-reviewed Journal for ImmunoTherapy in Cancer. Authored by Fanny Chapelin, Christian Capitini, and Eric Ahrens, the article reviews current research and assesses the potential of this technology to accelerate the clinical development of adoptive cell therapies involving T lymphocytes, NK cells, dendritic cells, and peripheral blood mononuclear cells. The paper also includes discussions of the evolving regulatory framework for clinical cell tracking data and current cell tracking research using other imaging modalities.

“We believe that cell trafficking data is critical to the clinical translation of engineered cell therapies in all solid tumor cancers. Relying solely on efficacy and adverse event endpoints in early clinical studies will lead to poor decisions regarding dosage, route of administration, and the use of co-therapies in later stage trials. The need for this type of data to support regulatory approval and reimbursement by payors is an emerging consensus,” said Charlie O’Hanlon, President and CEO of Celsense.

This paper is open access and is available at https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0416-9.

About Celsense
Celsense, Inc. develops and offers a novel product that enables the non-invasive imaging of cells in vivo using magnetic resonance imaging (MRI). The company’s lead product Cell Sense CS-1000 is a patented fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Cell Sense CS-1000 is the subject of a Drug Master File at US FDA and Health Canada and is the only clinical grade MRI cell tracking reagent available in North America. Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. Celsense’s mission is to be the

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870
charlie@celsense.com

Continue Exploring

Products

Papers

Real-Time Results,<br />Faster and More Accurate

Celsense offers products that enable real-time MRI detection of inflammation and cellular therapeutics. The mission of the company is to be the standard for cellular imaging in human health.

Send Us A Message

© 2018 Celsense, Inc. All rights reserved.